Skip to main content
Clinical Trials/NCT00186680
NCT00186680
Completed
Phase 1

Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment

Stanford University1 site in 1 country99 target enrollmentSeptember 1996
ConditionsBreast Cancer

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Stanford University
Enrollment
99
Locations
1
Primary Endpoint
Feasibility and safety
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.

Detailed Description

Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide \& Cisplatin for Stage IV Breast Cancer \& Limited Prior Treatment

Registry
clinicaltrials.gov
Start Date
September 1996
End Date
June 2005
Last Updated
16 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • stage IV breast cancer
  • primary breast cancer does not express CD34+
  • adequate organ function
  • no evidence of active infection

Exclusion Criteria

  • chemotherapy within 4 weeks
  • CNS disease

Outcomes

Primary Outcomes

Feasibility and safety

Secondary Outcomes

  • efficiency of mobilization
  • tumor contamination

Study Sites (1)

Loading locations...

Similar Trials